Eksenatid CAS:141758-74-9

Exenatide is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day.A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon. It is manufactured by Amylin Pharmaceuticals and commercialized by Astrazeneca.

Exenatide is the first of a new type of medication called incretin mimetics. The U.S. Food and Drug Administration (FDA) approved exenatide to treat people with type 2 diabetes who have not been able to control their blood sugar levels with oral medicines. It is given as a shot 2 times a day, before morning and evening meals. Incretin mimetics act like (mimic) the natural hormones in your body that lower blood sugar. These hormones are called incretins.

Exenatide is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day.

Exenatide is an injectable diabetes medicine that helps control blood sugar levels. This medication helps your pancreas produce insulin more efficiently. Byetta is a short-acting form of exenatide.This medication guide provides information about the Byettabrand of exenatide. Bydureon is another brand of exenatide that is not covered in this medication guide.

Exenatide is believed to facilitate glucose control in at least five ways:
1. Exenatide augments pancreas response and more appropriate amount of insulin that helps lower the rise in blood sugar from eating.
2. Exenatide also suppresses pancreatic release of glucagon, which prevents hyperglycemia (high blood sugar levels).
3. Exenatide helps slow down gastric emptying and thus decreases the rate at which meal-derived glucose appears in the bloodstream.
4. Exenatide has a subtle yet prolonged effect to reduce appetite, promote satiety via hypothalamic receptors.
5. Exenatide reduces liver fat content. Fat accumulation in the liver or nonalcoholic fatty liver disease (NAFLD) is strongly related with several metabolic disorders.